 Mitogen-Activated Protein Kinase Kinases
"Mitogen-Activated Protein Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.
| Descriptor ID |
D020929
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565 D08.811.913.696.620.682.725.200 D12.644.360.440 D12.776.476.440
|
| Concept/Terms |
Mitogen-Activated Protein Kinase Kinases- Mitogen-Activated Protein Kinase Kinases
- Mitogen Activated Protein Kinase Kinases
- MAPKKs
- MAPK Kinases
- Kinases, MAPK
- MAPKK
- Map Kinase Kinase
- Kinase Kinase, Map
- Kinase, Map Kinase
- MAP Kinase Kinases
- Kinase Kinases, MAP
- Kinases, MAP Kinase
MAPK-ERK Kinases- MAPK-ERK Kinases
- Kinases, MAPK-ERK
- MAPK ERK Kinases
- MEKs
- MAP-ERK Kinase
- Kinase, MAP-ERK
- MAP ERK Kinase
|
Below are MeSH descriptors whose meaning is more general than "Mitogen-Activated Protein Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "Mitogen-Activated Protein Kinase Kinases".
This graph shows the total number of publications written about "Mitogen-Activated Protein Kinase Kinases" by people in this website by year, and whether "Mitogen-Activated Protein Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 0 | 2 | 2 | | 1997 | 3 | 0 | 3 | | 1998 | 2 | 0 | 2 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 5 | 6 | | 2001 | 2 | 4 | 6 | | 2002 | 1 | 2 | 3 | | 2003 | 1 | 2 | 3 | | 2004 | 2 | 2 | 4 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 1 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 1 | 3 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 1 | 2 | | 2016 | 2 | 0 | 2 | | 2017 | 1 | 1 | 2 | | 2018 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Mitogen-Activated Protein Kinase Kinases" by people in Profiles.
-
Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma. Neurologist. 2018 Sep; 23(5):163-166.
-
Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018 07; 24(7):968-977.
-
Park JH, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 2017 Mar; 108(3):488-496.
-
Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 03 16; 543(7645):378-384.
-
Gonzalez AM, Hoffman JR, Townsend JR, Jajtner AR, Boone CH, Beyer KS, Baker KM, Wells AJ, Mangine GT, Robinson EH, Church DD, Oliveira LP, Fukuda DH, Stout JR. Intramuscular MAPK signaling following high volume and high intensity resistance exercise protocols in trained men. Eur J Appl Physiol. 2016 Sep; 116(9):1663-70.
-
Ikeda Y, Park JH, Miyamoto T, Takamatsu N, Kato T, Iwasa A, Okabe S, Imai Y, Fujiwara K, Nakamura Y, Hasegawa K. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6110-6117.
-
Kato T, Inoue H, Imoto S, Tamada Y, Miyamoto T, Matsuo Y, Nakamura Y, Park JH. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget. 2016 Apr 05; 7(14):17652-64.
-
Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
-
Akimova OA, Tverskoi AM, Smolyaninova LV, Mongin AA, Lopina OD, La J, Dulin NO, Orlov SN. Critical role of the a1-Na(+), K(+)-ATPase subunit in insensitivity of rodent cells to cytotoxic action of ouabain. Apoptosis. 2015 Sep; 20(9):1200-10.
-
Matsuo Y, Park JH, Miyamoto T, Yamamoto S, Hisada S, Alachkar H, Nakamura Y. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22; 6(259):259ra145.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|